References
- Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374(26):2563–2574. doi:10.1056/NEJMra1406182
- Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599–1613. doi:10.1002/art.41042
- Garcovich S, De Simone C, Genovese G, Berti E, Cugno M, Marzano AV. Paradoxical skin reactions to biologics in patients with rheumatologic disorders. Front Pharmacol. 2019;26(10):282. doi:10.3389/fphar.2019.00282
- Lubrano E, Scriffignano S, Perrotta FM. TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis. Expert Rev Clin Immunol. 2019;15(12):1303–1312. doi:10.1080/1744666X.2020.1685382
- Radner H, Aletaha D. Anti-TNF in rheumatoid arthritis: an overview. Wien Med Wochenschr. 2015;165(1–2):3–9. doi:10.1007/s10354-015-0344-y
- Aardoom MA, Veereman G, de Ridder L. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease. Int J Mol Sci. 2019;20(10):2529. doi:10.3390/ijms20102529
- Bae JM, Kwon HS, Kim GM, Park KS, Kim KJ. Paradoxical psoriasis following anti-TNF therapy in ankylosing spondylitis: a population-based cohort study. J Allergy Clin Immunol. 2018;142(3):1001–1003.e2. doi:10.1016/j.jaci.2018.05.015
- Havmose M, Thomsen SF. Development of paradoxical inflammatory disorders during treatment of psoriasis with TNF inhibitors: a review of published cases. Int J Dermatol. 2017;56(11):1087–1102. doi:10.1111/ijd.13691
- Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40(3):233–240. doi:10.1016/j.semarthrit.2010.04.003
- Ma HL, Napierata L, Stedman N, et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum. 2010;62(2):430–440. doi:10.1002/art.27203
- Dubash S, Bridgewood C, McGonagle D, Marzo-Ortega H. The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond. Expert Rev Clin Immunol. 2019;15(2):123–134. doi:10.1080/1744666X.2019.1561281
- Warren RB, Brnabic A, Saure D, et al. Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. Br J Dermatol. 2018;178(5):1064–1071. doi:10.1111/bjd.16140